Integrated BioPharma Reports Results for its Quarter Ended September 30, 2019

Wednesday, 13 November 2019 03:45 PM

Topic: 

Earnings

HILLSIDE, NJ / ACCESSWIRE / November 13, 2019 / Integrated BioPharma, Inc. (OTC BB:INBP) (the "Company") reports it financial results for the quarter ended September 30, 2019.

Revenue for the quarter ended September 30, 2019 was $11.4 million compared to $10.3 million for the quarter ended September 30, 2018, an increase of $1.1 million or 10.7%. The Company had operating income for the quarter ended September 30, 2019 of $0.5 million compared to operating income of $0.4 million for the quarter ended September 30, 2018.

For the quarter ended September 30, 2019, the Company had net income and diluted net income of $0.3 million or $0.01 per share of common stock, compared with net income and diluted net income of $0.2 million or $0.01 per share of common stock for the quarter ended September 30, 2018.

"We are excited to report that our revenue increased by approximately 11% in the quarter ended September 30, 2019 and that our revenue from our two significant customers in our Contract Manufacturing Segment remained consistent; representing approximately 91% and 89% of total revenue in the quarters ended September 30, 2019 and 2018, respectively," said Riva Sheppard, Co-Chief Executive Officer of the Company.

A summary of our financial results for the three months ended September 30, 2019 follows:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
           
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
           
(In thousands, except share and per share amounts)
           
(unaudited)
           
 
  Three Months Ended  
 
  September 30,  
 
  2019     2018  
 
           
Total revenue
  $  11,406     $  10,304  
Cost of sales
    10,007       9,085  
Gross profit
    1,399       1,219  
Selling and administrative expenses
    923       814  
Operating income
    476       405  
Other expense, net (1)
    (127 )     (191 )
 
               
Income before income taxes
    349       214  
Income tax expense, net
    37       55  
Net income
  $  312     $  159  
 
               
Net income per common share:
               
Basic
  $  0.01     $  0.01  
Diluted
  $  0.01     $  0.01  
Weighted average common shares outstanding:
               
Basic
    29,565,943       27,218,786  
Diluted
    30,724,633       27,963,604  
 
               
 
               
 
               
(1) Includes interest expense of $124 and $200, respectively.
               

SOURCE: Integrated BioPharma, Inc.